---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002132"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-02-08T23:59:59+00:00"
generated_at: "2026-06-19T21:49:18.488541+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara reports FY2022 net loss $228.3M, CFO transition, Ebvallo EU launch

## Summary
- Cash and investments $242.8M as of Dec 31, 2022; runway extended into Q2 2024.
- Net loss $228.3M ($2.24/share) for FY2022 vs $340.1M ($3.63/share) in FY2021.
- CFO Utpal Koppikar resigns effective March 31, 2023; Eric Hyllengren appointed CFO effective April 1, 2023.
- Ebvallo EU launch led by Pierre Fabre to begin Q1 2023; FDA discussions ongoing for tab-cel BLA.
- ATA188 Phase 2 EMBOLD primary data readout on track for October 2023.

## SEC filing metadata
- accession: 0000950170-23-002132
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/atra-20230203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002132
- JSON: https://secwatch.observer/filing/0000950170-23-002132.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002132.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the fourth quarter and fiscal year 2022, EPS $0.72 per share, and ... $2.24 per share.
  - Period: the fourth quarter and year ended December 31, 2022
  - Net income: $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the fourth quarter and fiscal year 2022
  - EPS: $0.72 per share, and ... $2.24 per share
  - Result: reported results
  source text: On February 8, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) announced certain financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm
- Executive change
  Utpal Koppikar resigned as Executive Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President, Chief Financial Officer
  source text: Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company, effective March 31, 2023, to pursue an external opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm
- Executive change
  Eric Hyllengren was appointed as Senior Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: Senior Vice President, Chief Financial Officer
  source text: the Company appointed Eric Hyllengren, the Company’s Senior Vice President, Finance, to serve as the Company’s Senior Vice President, Chief Financial Officer, effective as of April 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.